Your browser doesn't support javascript.
loading
Mechanisms of drug resistance in breast cancer liver metastases: Dilemmas and opportunities.
Yan, Chun-Yan; Zhao, Meng-Lu; Wei, Ya-Nan; Zhao, Xi-He.
Afiliação
  • Yan CY; Department of Clinical Oncology, Shengjing Hospital of China Medical University, Shenyang 110022, People's Republic of China.
  • Zhao ML; Department of Clinical Oncology, Shengjing Hospital of China Medical University, Shenyang 110022, People's Republic of China.
  • Wei YN; Department of Clinical Oncology, Shengjing Hospital of China Medical University, Shenyang 110022, People's Republic of China.
  • Zhao XH; Department of Clinical Oncology, Shengjing Hospital of China Medical University, Shenyang 110022, People's Republic of China.
Mol Ther Oncolytics ; 28: 212-229, 2023 Mar 16.
Article em En | MEDLINE | ID: mdl-36860815
ABSTRACT
Breast cancer is the leading cause of cancer-related deaths in females worldwide, and the liver is one of the most common sites of distant metastases in breast cancer patients. Patients with breast cancer liver metastases face limited treatment options, and drug resistance is highly prevalent, leading to a poor prognosis and a short survival. Liver metastases respond extremely poorly to immunotherapy and have shown resistance to treatments such as chemotherapy and targeted therapies. Therefore, to develop and to optimize treatment strategies as well as to explore potential therapeutic approaches, it is crucial to understand the mechanisms of drug resistance in breast cancer liver metastases patients. In this review, we summarize recent advances in the research of drug resistance mechanisms in breast cancer liver metastases and discuss their therapeutic potential for improving patient prognoses and outcomes.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article